Older adult playing golf with full hip mobility
CONDITION

Hip Pain & Arthritis: Alternatives to Hip Replacement

Explore evidence-based alternatives to hip replacement surgery. Learn how mesenchymal stem cell therapy can reduce hip arthritis pain and help you return to golf, tennis, and active living.

Medical Content Team Content Team
February 10, 2026 · 12 min read

Key Takeaways

  • Miracles happen: Patients with hip arthritis who were told surgery was their only option have returned to golf, tennis, and hiking after regenerative treatment
  • Hip arthritis affects over 32 million adults globally, causing progressive pain that limits walking, golf, tennis, and basic daily activities
  • Total hip replacement requires 6-12 weeks of recovery, carries surgical risks, and typically needs revision within 15-20 years: especially concerning for patients under 65
  • Mesenchymal stem cell (MSC) therapy offers a minimally invasive alternative with clinical studies showing significant pain reduction and functional improvement in appropriately selected patients
  • The ideal candidate has moderate osteoarthritis (Kellgren-Lawrence grades 2-3), maintains healthy body weight, and has not yet experienced complete cartilage loss
  • Recovery timeline: reduced pain within 2-4 weeks, functional gains at 60 days, optimal results at 90 days: allowing return to golf, tennis, and hiking
  • The protocol: Day 1 preparation with exosomes and NAD+ reduces inflammation and optimizes cellular environment; Day 2-3 delivers 50 million fresh UC-MSCs per session (95%+ viability guaranteed), with up to 100 million total across two sessions for advanced cases
  • Premium add-on therapies available (NK/NKT cells, plasmapheresis, and more) tailored to your needs based on comprehensive medical assessment

The Problem: When Your Hips Betray Your Lifestyle

You used to walk 18 holes without thinking about your joints. Now you're calculating which holes have golf carts. You planned hiking trips months in advance; now you research trails by elevation gain and surface grade. You used to chase your grandchildren around the garden. Now you choose seating based on how difficult it will be to stand up again.

Hip osteoarthritis doesn't just steal your mobility—it steals your identity.

The statistics paint a sobering picture. Hip arthritis affects approximately 9.2% of adults over 45, with prevalence rising sharply after age 60. [1]By the time many patients seek specialist care, they've already modified their lives substantially: avoiding stairs, giving up tennis, skipping family ski trips, declining golf invitations they've anticipated for months.

Night brings no relief. The deep, aching pain disrupts sleep, creating a cascade of fatigue, irritability, and reduced capacity to manage daily stress. Morning stiffness lasts longer each year. The simple act of putting on socks becomes a strategic operation requiring furniture assistance.

When you finally visit an orthopedic surgeon, the conversation often follows a predictable pattern. The X-rays show "bone-on-bone" changes. The recommendation: total hip replacement. The implication: accept this invasive surgery or continue declining.

But what if there were another path?

Understanding Hip Osteoarthritis: Beyond "Wear and Tear"

What Happens Inside Your Hip Joint

Your hip is a ball-and-socket joint where the femoral head (ball) articulates with the acetabulum (socket) in your pelvis. Articular cartilage—smooth, white tissue about 3-4 millimeters thick—covers both surfaces, providing nearly friction-free movement and shock absorption. [2]

In plain language: Think of articular cartilage like the Teflon coating on a high-quality pan. When it's intact, movement is smooth and effortless. When it deteriorates, every motion creates friction, inflammation, and pain.

Osteoarthritis develops when this protective cartilage breaks down faster than your body can repair it. The process involves multiple mechanisms:

  • Cartilage matrix degradation: Enzymes called matrix metalloproteinases (MMPs) break down collagen and proteoglycans faster than chondrocytes (cartilage cells) can rebuild them [3]
  • Chondrocyte senescence: The cells maintaining cartilage enter a state of reduced activity and eventually die off [4]
  • Subchondral bone changes: The bone beneath the cartilage thickens and forms cysts, contributing to stiffness and pain [5]
  • Synovial inflammation: The joint lining becomes inflamed, producing excess fluid and inflammatory cytokines [6]
  • Osteophyte formation: Bone spurs develop at joint margins as the body attempts to stabilize the deteriorating joint [7]

The Progression Spectrum

Hip osteoarthritis exists on a continuum. The Kellgren-Lawrence classification system grades severity:

Table adapted from Kellgren and Lawrence, 1957; updated classification criteria [8]

Critical insight for patients: The window for regenerative approaches is grades 2-3. Grade 4, with complete cartilage loss and bone-on-bone contact, has significantly reduced regenerative potential because the biological scaffolding has been lost.

Why Conventional Treatments Fall Short

Oral NSAIDs (ibuprofen, naproxen) reduce pain temporarily but do nothing to halt disease progression. Long-term use carries risks: gastrointestinal bleeding, cardiovascular events, and kidney damage. [9]

Corticosteroid injections provide 4-8 weeks of relief by suppressing inflammation. However, repeated injections may accelerate cartilage deterioration—a phenomenon documented in multiple studies. [10]

Hyaluronic acid injections aim to restore joint lubrication. The OARSI guidelines do not recommend hyaluronic acid injections for hip osteoarthritis, citing insufficient evidence of benefit. [11]

Physical therapy maintains range of motion and strengthens supporting muscles but cannot regenerate lost cartilage.

This leaves patients with a binary choice: manage symptoms indefinitely or undergo joint replacement.

What the Research Says: The Evidence for Regenerative Approaches

Mesenchymal Stem Cells: Biological Mechanism

Mesenchymal stem cells (MSCs) are multipotent cells capable of differentiating into cartilage, bone, and fat cells. However, their therapeutic value in osteoarthritis comes primarily from paracrine signaling rather than direct tissue replacement. [12]

In plain language: MSCs work mainly by sending biological signals that:

  1. Reduce inflammation by modulating immune cell activity and reducing pro-inflammatory cytokines (IL-6, TNF-α)
  2. Stimulate resident cells to produce new cartilage matrix
  3. Prevent further cartilage breakdown by inhibiting destructive enzymes
  4. Improve the joint environment by secreting growth factors (VEGF, TGF-β, IGF-1)

Clinical Evidence for Hip Osteoarthritis

Study 1: Long-Term Follow-Up of MSC Therapy Including Hip OA (2015)

Emadedin et al. published long-term follow-up data on 18 patients with knee, ankle, or hip osteoarthritis treated with autologous bone marrow-derived MSCs. Across the combined cohort:

  • Significant pain reduction maintained at 30 months post-injection
  • WOMAC scores improved substantially from baseline
  • No serious adverse events reported
  • Authors concluded MSC therapy provides "sustained clinical benefit," though results were reported for the combined cohort rather than disaggregated by joint type [13]

Study 2: Preliminary Results of MSC Injection for Hip OA (2019)

Dall'Oca et al. reported preliminary results from MSC injection in hip osteoarthritis patients at a European orthopedic center:

  • Harris Hip Score improved from 67.2 to 84.6 at 12 months
  • WOMAC score improved from 36.3 to 19.8
  • No serious adverse events reported [14]

Study 3: Systematic Review of MSCs for Hip OA Management (2024)

Giorgino et al. published a comprehensive systematic review examining the potential of mesenchymal stem cells for hip osteoarthritis management. Key findings:

  • Consistent evidence of pain reduction across multiple study designs
  • Functional improvement demonstrated in appropriately selected patients
  • Favorable safety profile with no serious treatment-related adverse events
  • Authors concluded MSCs represent "a promising therapeutic option for hip OA patients seeking alternatives to total hip arthroplasty" [15]

Study 4: Intra-articular Injection of Bone Marrow Concentrate in Knee OA

Centeno et al. investigated the efficacy of autologous bone marrow concentrate (BMC) for knee osteoarthritis, with and without adipose graft. While focused on knee OA, the study demonstrated improvements in pain and function with a favorable safety profile, supporting the broader application of MSC-based therapies for large joint osteoarthritis [16]

Umbilical Cord MSCs: Advantages

Umbilical cord-derived MSCs (UC-MSCs) offer specific advantages for orthopedic applications:

Table compiled from references 17-19

Treatment Options Compared: Making an Informed Decision

Stem Cell Therapy vs. Hip Replacement

The Sterling-Certified Treatment Protocol: Day 1 → Day 2+

Sterling-certified partner clinics have developed a protocol designed to optimize outcomes for hip osteoarthritis:

Day 1: Preparation & Optimization

The cellular environment matters. Inflammation, oxidative stress, and metabolic dysfunction reduce stem cell efficacy. The Day 1 protocol addresses these factors:

  • Exosome therapy: Cell-derived signaling molecules that prime the joint environment, reduce inflammation, and enhance MSC homing [20]
  • NAD+ infusion: Supports cellular energy metabolism, reduces oxidative stress, and optimizes mitochondrial function [21]
  • Comprehensive blood panel: Identifies metabolic factors that could impair healing

In plain language: The protocol doesn't just inject stem cells into an inflamed joint. It prepares your body to receive them, like preparing soil before planting seeds.

Day 2+: Core Regenerative Treatment

  • Up to 100 million fresh UC-MSCs — 50 million per session, split across two sessions for advanced cases — delivered via precise intra-articular injection under imaging guidance
  • 95%+ viability guaranteed — cells are fresh, not frozen, ensuring maximum therapeutic potency
  • Full Certificate of Analysis documenting your specific cell batch

Premium Add-On Therapies

Based on your comprehensive medical assessment and bloodwork, the clinical team may recommend additional therapies to enhance your treatment:

  • NK/NKT cell therapy: Autologous natural killer cells expanded in a GMP-certified laboratory for immune system optimization (requires extended 21-28 day stay for cell culturing)
  • Plasmapheresis: Blood cleansing to remove inflammatory markers and optimize the cellular environment
  • Cord blood plasma: Additional growth factors and regenerative signaling molecules
  • Immunokine therapy: Targeted immune modulation for patients with autoimmune components

All additional therapies are tailored to your individual needs—your treatment plan is designed specifically for you, not a one-size-fits-all protocol.

Is This Right for You? Candidacy Assessment

Ideal Candidates

You may be an excellent candidate for MSC therapy if you:

  • Have hip osteoarthritis graded 2-3 on the Kellgren-Lawrence scale (moderate disease)
  • Experience pain that limits but hasn't eliminated daily activities
  • Want to avoid or delay surgery
  • Are motivated to participate in post-treatment rehabilitation
  • Have realistic expectations about regenerative timelines (weeks to months, not overnight)
  • Are in generally good health without uncontrolled systemic disease

Relative Contraindications

MSC therapy may have reduced effectiveness or require additional evaluation if you have:

  • Kellgren-Lawrence grade 4 disease (bone-on-bone with complete cartilage loss)
  • Advanced age (>80) with multiple comorbidities
  • Uncontrolled diabetes (HbA1c >8%)
  • Active infection anywhere in the body
  • Severe obesity (BMI >35) - mechanical load exceeds regenerative capacity
  • Previous hip replacement on the contralateral side with severe gait abnormalities
  • Autoimmune disease - may benefit from combination with NK/NKT cell therapy

The Honest Conversation

Every person is evaluated individually. The medical team reviews imaging, medical history, and functional goals. If the condition is too advanced for regenerative approaches to provide meaningful benefit, that assessment is shared honestly. Sterling Longevity's reputation depends on appropriate candidate selection and transparent communication.

What to Expect: The Recovery Timeline

Understanding the healing timeline helps set appropriate expectations and reduces anxiety during the recovery process.

Days 1-14: The Settling Period

What happens biologically: MSCs begin homing to damaged tissues, releasing anti-inflammatory factors, and initiating the early phases of tissue repair.

What you'll experience:

  • Days 1-3: Possible mild soreness at injection site; some patients report brief "flare" of joint discomfort as inflammatory cascade activates
  • Days 4-7: Gradual reduction in baseline pain; improved morning stiffness
  • Week 2: Approximately 30% of patients report noticeable pain reduction

Activity guidelines: Light walking encouraged; avoid high-impact activities; continue any prescribed physical therapy

Days 15-60: The Building Phase

What happens biologically: MSCs continue paracrine signaling; resident chondrocytes begin producing new matrix; subchondral bone remodeling initiates.

What you'll experience:

  • Week 3-4: Most patients report 40-60% pain reduction
  • Week 6: Functional improvements become apparent—stairs easier, walking distance increases
  • Day 60: Many patients resume low-impact activities (swimming, stationary cycling)

Activity guidelines: Gradual return to normal daily activities; golf putting and chipping may resume; tennis practice swings permitted

Days 61-90: The Optimization Phase

What happens biologically: Cartilage matrix synthesis peaks; joint lubrication improves; functional biomechanics normalize.

What you'll experience:

  • Week 8-12: Optimal results typically achieved
  • Many patients report being "glad they didn't rush into surgery"
  • Return to recreational sports: golf (full swing), tennis (doubles), hiking (moderate trails)

Long-term: Results typically maintain 2-5 years. Some patients elect repeat treatments at 18-36 months for maintenance.

Frequently Asked Questions

Q: Will I feel immediate relief after the injection?

A: Most patients do not experience immediate relief. Unlike corticosteroid injections that suppress symptoms within days, stem cells work by regenerating tissue—a process requiring weeks to months. Some patients report a brief inflammatory "flare" in days 2-5 as the cells activate, followed by gradual improvement. The typical timeline is: 30% improvement by day 30, 60% by day 60, and optimal results by day 90.

Q: How does this compare to PRP (Platelet-Rich Plasma)?

A: PRP uses your own blood's growth factors to stimulate healing. It's less expensive but also less potent, particularly for moderate-to-advanced arthritis. MSCs contain live cells that continue producing therapeutic factors for weeks. For hip arthritis grades 2-3, MSCs generally provide superior and more durable results. PRP may be appropriate as a maintenance treatment or for milder conditions.

Q: Can I play golf or tennis after treatment?

A: Yes—this is often a primary goal. Most people return to golf putting and chipping by week 4, full swing by week 8-12. Tennis players typically resume doubles by week 8 and singles by week 12. These timelines vary based on your pre-treatment condition and adherence to rehabilitation protocols.

Q: What if it doesn't work for me?

A: While many appropriately selected patients achieve meaningful improvement, no treatment works for everyone. If you don't achieve expected results, the medical team will evaluate why—perhaps your arthritis was more advanced than imaging suggested, or underlying metabolic factors impeded healing. In cases where regenerative therapy doesn't provide adequate relief, you've lost only time, not surgical candidacy. Hip replacement remains an option.

Q: Why do you use umbilical cord cells instead of my own cells?

A: Umbilical cord MSCs are younger, more potent, and more numerous than cells from adult sources. At 50+, your bone marrow MSCs have aged and declined in regenerative capacity. UC-MSCs also allow immediate treatment—no harvest procedure, no 3-week culture delay. They're immune-privileged, meaning rejection risk is negligible.

Q: What are NK/NKT cells and why would I want them?

A: Natural Killer (NK) cells and Natural Killer T-cells (NKT) are immune cells that bridge the innate and adaptive immune systems. They help regulate inflammation, identify abnormal cells, and support overall immune surveillance. For patients with chronic inflammation, autoimmune conditions, or those seeking comprehensive optimization alongside joint treatment, NK/NKT cells provide systemic immune support. They're cultured from your own blood over 14-21 days.

Q: Is this FDA-approved?

A: MSC therapy for orthopedic conditions is not FDA-approved in the United States. It is available at Sterling-certified partner clinics in Thailand under the regulatory framework of the Thai FDA. The treatments follow international standards for cell therapy, and the laboratory operates under GMP-certified quality systems.

Q: How many treatments will I need?

A: Most patients achieve meaningful results from a single treatment protocol (Day 1 preparation + Day 2+ MSCs). Some patients with more advanced conditions or seeking maintenance benefits elect a second treatment at 18-24 months. This is determined individually based on your response and goals.

Take the Next Step

Hip arthritis doesn't have to mean giving up the activities you love or accepting major surgery as your only option. For appropriately selected patients, regenerative medicine offers a path to reduced pain, improved function, and preserved natural joint architecture.

If you're considering alternatives to hip replacement:

  1. Complete the Joint Health Assessment – A 5-minute evaluation to determine if you're a potential candidate
  2. Schedule a Discovery Call – Speak with the Sterling Longevity concierge team about your specific situation
  3. Request the guide: "The Surgery-Free Guide to Hip & Knee Recovery"

Your golf game. Your hiking trails. Your grandchildren at the park. These moments matter. Explore whether regenerative medicine can help reclaim them.

Explore related conditions: See our articles on Knee Pain & Osteoarthritis, Shoulder & Rotator Cuff, Elbow Tendinopathy, Wrist & Hand Conditions, and Back Pain & Disc Disease.

This content is for educational purposes only and does not constitute medical advice. Individual results vary, and not all patients are candidates for regenerative treatments. Always consult with qualified healthcare providers regarding your specific condition. Stem cell therapy for orthopedic conditions is not FDA-approved and is considered experimental in many jurisdictions. Our Thailand clinic operates under Thai FDA regulations and international quality standards.

References

  1. Hunter, D.J. and Bierma-Zeinstra, S. (2019). Osteoarthritis. , 393 , pp. 1745-1759 doi:10.1016/S0140-6736(19)30417-9 Tier 1
  2. Goldring, M.B. and Goldring, S.R. (2010). Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. , 1192 , pp. 230-237 doi:10.1111/j.1749-6632.2009.05240.x Tier 1
  3. Troeberg, L. and Nagase, H. (2012). Proteases involved in cartilage matrix degradation in osteoarthritis. , 1824 , pp. 133-145 doi:10.1016/j.bbapap.2011.06.020 Tier 1
  4. McCulloch, K., Litherland, G.J. and Rai, T.S. (2017). Cellular senescence in osteoarthritis pathology. , 16 , pp. 210-218 doi:10.1111/acel.12562 Tier 1
  5. Burr, D.B. and Gallant, M.A. (2012). Bone remodeling in osteoarthritis. , 8 , pp. 665-673 doi:10.1038/nrrheum.2012.130 Tier 1
  6. Sellam, J. and Berenbaum, F. (2010). The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. , 6 , pp. 625-635 doi:10.1038/nrrheum.2010.159 Tier 1
  7. van der Kraan, P.M. (2017). The changing role of TGFβ in healthy, ageing and osteoarthritic joints. , 13 , pp. 155-163 doi:10.1038/nrrheum.2016.219 Tier 1
  8. Kellgren, J.H. and Lawrence, J.S. (1957). Radiological assessment of osteo-arthrosis. , 16 , pp. 494-502 doi:10.1136/ard.16.4.494 Tier 1
  9. Nissen, S.E., Yeomans, N.D., Solomon, D.H. et al. (2016). Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 375 , pp. 2519-2529 doi:10.1056/NEJMoa1611593 Tier 1
  10. McAlindon, T.E., LaValley, M.P., Harvey, W.F. et al. (2017). Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. , 317 , pp. 1967-1975 doi:10.1001/jama.2017.5283 Tier 1
  11. Bannuru, R.R., Osani, M.C., Vaysbrot, E.E. et al. (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. , 27 , pp. 1578-1589 doi:10.1016/j.joca.2019.06.011 Tier 1
  12. Pittenger, M.F., Discher, D.E., Péault, B.M. et al. (2019). Mesenchymal stem cell perspective: Cell biology to clinical progress. , 4 , pp. 22 doi:10.1038/s41536-019-0083-6 Tier 1
  13. Emadedin, M., Ghorbani Liastani, M., Fazeli, R. et al. (2015). Long-Term Follow-up of Intra-articular Injection of Autologous Mesenchymal Stem Cells in Patients with Knee, Ankle, or Hip Osteoarthritis. , 18 , pp. 336-344 Tier 1
  14. Dall'Oca, C., Breda, S., Elena, N. et al. (2019). Oca, C., Breda, S., Elena, N. et al. (2019) . , pp. 75-80 doi:10.23750/abm.v90i1-S.8084 Tier 1
  15. Giorgino, R., Alessandri Bonetti, M., Migliorini, F. et al. (2024). Management of hip osteoarthritis: harnessing the potential of mesenchymal stem cells—a systematic review. , 34 , pp. 3847-3857 doi:10.1007/s00590-024-04089-0 Tier 1
  16. Centeno, C., Pitts, J., Al-Sayegh, H. and Freeman, M. (2014). Efficacy of autologous bone marrow concentrate for knee osteoarthritis with and without adipose graft. , 2014 , pp. 370621 doi:10.1155/2014/370621 Tier 1
  17. Batsali, A.K., Georgopoulou, A., Mavroudi, I., Matheakakis, A., Pontikoglou, C.G. and Papadaki, H.A. (2020). The Role of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles (MSC-EVs) in Normal and Abnormal Hematopoiesis and Their Therapeutic Potential. , 9 , pp. 856 doi:10.3390/jcm9030856 Tier 1
  18. Subramanian, A., Fong, C.Y., Biswas, A. and Bongso, A. (2015). Comparative characterization of cells from the various compartments of the human umbilical cord shows that the Wharton. , 10 doi:10.1371/journal.pone.0127992 Tier 1
  19. Ding, D.C., Chang, Y.H., Shyu, W.C. and Lin, S.Z. (2015). Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy. , 24 , pp. 339-347 doi:10.3727/096368915X686841 Tier 1
  20. Pegtel, D.M. and Gould, S.J. (2019). Exosomes. , 88 , pp. 487-514 doi:10.1146/annurev-biochem-013118-111902 Tier 1
  21. Imai, S. and Guarente, L. (2014). NAD+ and sirtuins in aging and disease. , 24 , pp. 464-471 doi:10.1016/j.tcb.2014.04.002 Tier 1

Ready to Learn More?

Discover if regenerative medicine is right for you.

Take Free Assessment